IFNB1 and COVID-19: Notably, early data suggest a potential benefit for taking interferon beta on exposure to SARS-CoV-220; currently, trials are underway to study the efficacy of interferon beta in COVID-19.21,22 In this study, fumarates and natalizumab were each associated with reduced risk of ICU admission and/or ventilation compared with those not receiving therapy.